Literature DB >> 6839219

Rapid high-performance liquid chromatographic analysis of amiodarone and N-desethyl-amiodarone in serum.

J F Brien, S Jimmo, P W Armstrong.   

Abstract

A rapid and reliable high-performance liquid chromatographic (HPLC) assay has been developed for the measurement of the antiarrhythmic drug, amiodarone (A), and its metabolite, N-desethyl-amiodarone (NDA), in serum. The procedure involves addition of absolute ethanol to serum, previously adjusted to pH 6, followed by centrifugation. The supernatant is analyzed by reverse-phase HPLC with ultraviolet-visible detection. There is no intereference from endogenous substances or other commonly used antiarrhythmic agents. The mean overall accuracy of the HPLC assay is 96.9 +/- 9.1 (SD)% (n = 37) for A over the concentration range 0.10-10.00 micrograms/mL, and 99.8 +/- 4.8 (SD)% (n = 32) for NDA over the concentration range 0.10-7.50 micrograms/mL. The within-day coefficient of variation is less than 7% for A and NDA. The lower limit of quantitative sensitivity is 0.10 micrograms/mL for A and NDA, and the lower limit of qualitative detection is 1.0 ng for both compounds.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6839219     DOI: 10.1139/y83-038

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  3 in total

1.  Effect of amiodarone on 3H-ouabain binding sites in human skeletal muscle.

Authors:  A Nørgaard; J H Jensen; F Andreasen
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Effects of long-term oral administration of amiodarone on the electromechanical performance of rabbit ventricular muscle.

Authors:  I Kodama; R Suzuki; K Kamiya; H Iwata; J Toyama
Journal:  Br J Pharmacol       Date:  1992-10       Impact factor: 8.739

3.  Effects of chronic amiodarone treatment on cat myocardial phospholipid content and on in vitro phospholipid catabolism.

Authors:  N A Shaikh; E Downar
Journal:  Mol Cell Biochem       Date:  1987-11       Impact factor: 3.396

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.